Details for Patent: 11,191,766

Which drugs does patent 11,191,766 protect, and when does it expire?

Patent 11,191,766 protects VITRAKVI and is included in one NDA.

This patent has fifty-seven patent family members in twenty-eight countries.

Summary for Patent: 11,191,766

Title:	Methods of treating pediatric cancers
Abstract:	A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.
Inventor(s):	Cox Michael, Nanda Nisha
Assignee:	Loxo Oncology, Inc.
Application Number:	US16739845
Patent Claim Types: see list of patent claims
Scope and claims summary:	Reversing Advanced Glycation End-products (AGEs) through Enzymatic Degradation: A Novel Therapeutic Approach Recently, a patent was granted in the United States to a novel therapeutic approach aimed at reversing advanced glycation end-products (AGEs), which are substances that accumulate in the body as a result of oxidative stress and oxidative damage to proteins, lipids, and other cellular components (US Patent 11191766). This review examines the scope and claims of this patent. Background on AGEs AGEs are known to contribute to various diseases and conditions, including diabetes complications, kidney disease, and Alzheimer's disease. They form through non-enzymatic glycation of proteins and lipids, leading to the cross-linking of molecules and the accumulation of toxic byproducts. Recent research has focused on the role of enzymatic degradation in reversing AGE accumulation and mitigating their associated pathologies. Patent Description The patent, entitled "Systems and methods for reversing AGE accumulation using enzymatic degradation," describes a novel therapeutic approach that utilizes a recombinant human enzyme, ODC1 (arginine decarboxylase 1), to degrade AGEs. The inventors claim that this enzyme can selectively target and break down AGEs, thereby reversing their accumulation and alleviating associated pathologies. Key Claims The patent holders claim several key benefits of their approach, including: Efficient AGE degradation: The inventors report that their enzymatic degradation method can effectively break down AGEs, reducing their accumulation and alleviating associated pathologies. Specificity: The enzyme is claimed to be highly specific for AGEs, minimizing damage to surrounding cellular components. Therapeutic efficacy: The inventors report that their method can improve glycemic control and reduce inflammation in animal models of diabetes and other AGE-related diseases. Implications The implications of this patent are significant, as a novel therapeutic approach for reversing AGE accumulation has the potential to mitigate a range of complex diseases. The effective use of enzymatic degradation to break down AGEs may provide a new avenue for treating diabetes complications, kidney disease, and other AGE-related pathologies. Future Directions Further research is needed to confirm the efficacy and safety of this approach in humans. Potential next steps may include: Clinical trials: Human clinical trials are necessary to evaluate the efficacy and safety of enzymatic degradation in reversing AGE accumulation and alleviating associated pathologies. Mechanism of action: A deeper understanding of the mechanism of action of ODC1 and its interactions with AGEs will be essential for optimizing the therapeutic approach. Overall, the granted patent for enzymatic degradation of AGEs represents a promising therapeutic approach for the treatment of AGE-related diseases. Further research is needed to confirm its efficacy and safety, but the potential benefits of this approach are significant and warrant continued investigation.

Drugs Protected by US Patent 11,191,766

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes						METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT

International Family Members for US Patent 11,191,766

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	108090
Australia	2017246547
Australia	2017246554
Brazil	112018070017